Background: New methods are needed to improve health behaviors, such as adherence to colorectal cancer (CRC) screening. Personalized genetic information to guide medical decisions is increasingly available. Whether such information motivates behavioral change is unknown.
G
enetic testing for cancer susceptibility is offered most frequently for single-gene disorders. A mutation in the adenomatous polyposis coli gene (APC) confers a risk for colorectal cancer (CRC) of approximately 90% (1) . Identification of this mutation substantially affects clinical practice. However, cancer usually does not arise from single mutations. Instead, susceptibility results from the modest contributions of many genes, usually with environmental interaction. Identification of these genes and their modifiers is an active area of research (2) .
Genetic and environmental risk assessment (GERA) for common diseases is anticipated to become a widespread component of health care (3, 4) . We assessed polymorphic variants of methylenetetrahydrofolate reductase (MTHFR), an important regulator of cellular folate metabolism. Specific MTHFR polymorphisms are associated with variable susceptibility to CRC (5) (6) (7) (8) . Epidemiologic data also support a link between serum folate levels and CRC risk (9) . Assessment of the genetic (MTHFR) and environmental (serum folate levels) interaction is attractive because data that allow for CRC risk stratification among average-risk persons already exist. Specific polymorphisms in combination with low serum folate levels increase risk for CRC by approximately 1.5 to 2.0 times the baseline risk in white and African American persons in the United States (8) .
Unlike with genetic testing for high-risk persons, such as those with familial adenomatous polyposis, little is known about the impact on health behaviors or the psychological effects of providing average-risk persons with moderately predictive genetic information (4, 10 -13) . Understanding the benefits and harms of such testing in average-risk persons is important because similar testing is marketed directly to the public in an unsupervised manner (14).
We did a prospective, randomized, controlled trial to assess the effect of GERA feedback on CRC screening among average-risk persons who did not adhere to screening recommendations at study entry. Prevention of CRC is an optimal area to study the emerging role of moderately predictive genetic testing. Colorectal cancer is the second leading cause of cancer death in the United States (15) . Screening can reduce disease incidence and mortality (16) .
Our primary hypothesis was that providing personalized GERA information would increase CRC screening uptake compared with usual care. Further, we anticipated that participants characterized as having elevated risk by GERA would undergo screening more than those at average risk. Although MTHFR and serum folate level testing provided personalized risk information, our study did not intend to evaluate the specific predictive value of this combination for colorectal neoplasia.
METHODS

Design Overview
We did a randomized, controlled trial to compare CRC screening utilization in the GERA group versus the usual care (control) group and to detect differences in screening proportion between the average-and elevatedrisk GERA groups (12) . To increase the statistical power for comparisons within the GERA group, participants were randomly assigned in a 2:1 ratio to GERA or usual care, respectively. Participants provided survey data at baseline, 3 weeks, and 6 months and agreed to medical record review to ascertain CRC screening status. Those in the GERA group also participated in GERA counseling and disclosure sessions and had blood drawn for genotyping and measurement of serum folate levels.
Setting and Participants
Participants in this institutional review boardapproved trial were recruited from 4 internal and family medicine practices affiliated with Thomas Jefferson University, Philadelphia, Pennsylvania. We searched scheduling, billing, and medical records databases and applied filters matching eligibility requirements, including 1) age between 50 and 79 years; 2) average-risk status for CRC, defined as being asymptomatic and having no history of colorectal adenomas, cancer, or inflammatory bowel disease or no family history of familial adenomatous polyposis, hereditary nonpolyposis CRC, or CRC in a first-degree relative; 3) nonadherence to CRC screening guidelines at study initiation, defined as not having had home fecal occult blood testing in the past 12 months, barium enema or flexible sigmoidoscopy in the past 5 years, or colonoscopy in the past 10 years; 4) not receiving antibiotics or antifolate medications (for example, sulfasalazine or methotrexate) within the past 6 weeks; and 5) the ability to speak English.
Potential participants were mailed a letter outlining the study (Supplement 1, available at www.annals.org), a pamphlet reviewing standard CRC screening options, a consent form, and information on how to opt out of the study. We telephoned participants who had not opted out, confirmed eligibility, obtained verbal consent, and administered a baseline survey about demographic characteristics and history of medical illnesses and multivitamin use. Participants also responded to previously described questionnaires about knowledge of CRC screening and the possible role of genes and diet in cancer development (17) . Finally, they completed the Impact of Event Scale (IES) questionnaire, a well-validated assessment tool for psychological distress (18) .
Randomization and Intervention
Study group allocation was implemented by a secure, Web-based application using randomization tables generated before the study started.
GERA Intervention Group
Participants randomly assigned to GERA met with specially trained study nurses rather than genetic counselors. This research design reflected an effort to study feasible approaches to disclosure of genetic test results that could be incorporated into primary care settings, because the number of genetic counselors seems inadequate to meet health service needs even in high-risk settings (19) . Study nurses were trained by genetic counselors before study initiation and regularly monitored disclosure sessions to ensure process uniformity.
Using a standardized study pamphlet describing GERA, the nurse and intervention participants together reviewed the purpose of GERA, the potential results from genotyping and serum folate level measurement, and how results would be disclosed. A basic description of genes and their importance in cancer was provided. An average lifetime risk for CRC of 1 in 20 was described.
Participants were told that their GERA results would be classified as "elevated" or "average." The study nurse
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Genetic and environmental risk assessment (GERA), in which related genetic and environmental information identifies an individual's risk for a disease, has been suggested as a means to motivate adherence to recommended cancer screening.
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Original Research Risk Assessment and Colorectal Cancer Screening explained that an elevated result did not guarantee disease but was only one potential risk factor for CRC, suggesting modestly increased risk compared with that of a similarly aged person. Conversely, the nurse stated that an average result did not ensure protection against CRC now or in the future but simply indicated the absence of this risk factor. The study nurse emphasized that GERA was a method to stratify CRC risk but was not intended to be a substitute for screening.
Venipuncture was done to assess serum folate levels and MTHFR polymorphisms for participants randomly assigned to GERA. Serum folate levels were analyzed in a single commercial laboratory using a standard 125 I RIA kit with controls. All genotyping was done at the Fox Chase Cancer Center Cancer Genomics Facility, Philadelphia, Pennsylvania. After DNA was extracted, separate polymerase chain reaction amplifications of exons 4 and 7 of the MTHFR gene were completed, followed by pyrosequencing specific for codons 677 and 1298.
The GERA-associated CRC risk was characterized by particular combinations of age-specific serum folate levels and MTHFR polymorphisms (Appendix Table 1 , available at www.annals.org); MTHFR is an important regulator of cellular folate metabolism. Separately, MTHFR polymorphic variant or serum folate level is associated with variable susceptibility to CRC (5, 6, 9, 20, 21) . Most persons with compound genotype combinations have a modestly elevated CRC risk in the setting of low serum folate levels compared with carriers of these same genotypes with normal serum folate levels or persons with less common combinations (TT/AA and CC/CC), regardless of serum folate levels (8, 22, 23) . Low serum folate level status was conventionally assigned to any person in the 25th percentile or below for age-based population normal values, according to data from NHANES (National Health and Nutrition Examination Survey) at study commencement (24) .
Within 2 weeks of blood collection, GERA results were disclosed and explained to every participant, first by telephone and then by mail (Supplement 2, available at www.annals.org). In the disclosure session, the same points about multiple potential risk factors (GERA being only one) were emphasized, as was the importance of screening regardless of GERA result.
Usual Care (Control) Group
Usual care recipients completed the same baseline questionnaire as GERA recipients; however, they did not meet with a study nurse, discuss GERA, participate in decision counseling, or provide a blood sample. Regardless of study group or risk, all participants were encouraged to have screening.
Outcomes and Follow-up
Control and intervention recipients subsequently received a 2-card fecal immunochemical test kit with instructions to minimize the effect of variable access to CRC screening and answered 3-week and 6-month postenrollment questionnaires administered by telephone. These questionnaires asked about CRC screening utilization and repeated the IES assessment.
As part of the postvisit 3-week and 6-month telephone questionnaires, participants randomly assigned to GERA were also asked about receipt of counseling and GERA results. Participants who recalled receiving GERA results were given the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire, which measures psychological reactions specific to genetic testing (25) . This questionnaire features 3 subscales: distress, uncertainty, and positive experiences (a higher score reflects fewer positive experiences).
The primary study outcome of CRC screening within 6 months of enrollment was calculated on the basis of electronic and manual medical chart review. Electronic reviews were done first, searching for completion date of any screening test (fecal occult blood testing, sigmoidoscopy, barium enema, or colonoscopy). If no electronic entry was found, paper charts were reviewed. Chart abstractors were blinded to study group allocation.
Statistical Analysis
A target sample size of 1760 participants was selected to provide 80% power to detect a clinically relevant 10% absolute difference between the proportion of participants screened in the elevated-and average-risk subsets of the GERA group. This sample size also provided 99% power to detect a 10% absolute difference in the screening proportions between the usual care and GERA groups.
As planned, the study's data and safety monitoring board did periodic interim analyses to monitor the effect of the GERA intervention. When the data and safety monitoring board recognized that the effect of the intervention was substantially smaller than hypothesized, they recommended stopping recruitment because further enrollment was unlikely to yield statistically significant differences for increased screening in the intervention group.
Potential confounders associated with CRC screening identified from a priori literature reviews were compared across study groups by using chi-square and Wilcoxon rank-sum tests for categorical and continuous variables, respectively. Factors examined included age; sex; race; marital status; education level; regular multivitamin use; and scores for the IES, a CRC screening knowledge scale, and a genetics and diet knowledge scale. An IES score of 26 or greater indicated higher stress on the basis of standard convention (18) .
The primary efficacy analysis used univariate logistic regression to compare the proportions of participants completing CRC screening within 6 months of enrollment between study groups. Statistical significance was assessed by the Wald chi-square test. Following intention-to-treat methods, the primary outcome analysis included all enrolled participants. Participants without chart audit infor-
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In the GERA group, the association of GERA risk (elevated vs. average) with CRC screening was evaluated in a similar way. Participants randomly assigned to the GERA group who did not receive GERA results because of laboratory error, blood not being drawn, or not having GERA counseling were excluded from this analysis (n ϭ 77). To explore whether a substantial imbalance in the proportion of participants with unknown GERA risk across risk groups would affect the study's results, we did sensitivity analyses in the GERA group. We considered 2 extremes: that all participants with unknown risk had either average or elevated risk.
Univariate logistic regression was used to assess the association of potential baseline confounders with CRC screening. Participants with missing values for a baseline variable were excluded from analyses involving that variable. The same approach was used to evaluate the relationships between baseline factors and the proportion of participants in the GERA group defined as having elevated risk.
Multivariable logistic models were fit to the data to assess the effect of the primary intervention on CRC screening after adjustment for potential confounders. Covariates in these models included study group allocation and all a priori defined potential confounders. The effect is reported as an adjusted odds ratio (OR) and 95% 2-sided CI. A second multivariable model was fit to data from participants in the GERA group only to evaluate the effect of GERA risk on CRC screening adherence after these same potential confounders were adjusted for.
Propensity score-based analyses were done to further assess the effect of GERA risk on screening after confounding was controlled for. The details of these analyses are described in the Appendix (available at www.annals.org).
Univariate logistic models were used to explore the associations of CRC screening status and GERA risk with MICRA scores among participants in the GERA group. All tests were 2-sided using a 5% type I error, and analyses were done using SAS software, version 9.3 (SAS Institute), and Stata, version 12 (StataCorp).
Role of the Funding Source
This study was supported by the National Institutes of Health. The funding source had no role in the design, conduct, or reporting of this study or in the decision to submit the manuscript for publication.
RESULTS
A total of 783 participants were randomly assigned and completed the baseline survey ( Figure) . Table 1 presents baseline demographic characteristics, multivitamin use, and psychometric and knowledge characteristics. Nearly one half of the participants were married, and 56% were white. Most had at least some college education. Across study groups, there were no significant differences in any of these variables. At baseline, multivitamin use, IES score, and assessments of knowledge about CRC screening CRC ϭ colorectal cancer; GERA ϭ genetic and environmental risk assessment.
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and genes and diet were similar in participants randomly assigned to either group. Table 2 shows that CRC screening at 6 months was similar for the GERA and usual care groups. In both groups, approximately one third of participants completed screening during follow-up. The unadjusted OR for CRC screening for GERA versus usual care was 0.89 (95% CI, 0.65 to 1.21).
Although the covariates were well-balanced in the 2 groups, we did additional analyses to assess the effect of potential confounders on the association between screening and study group. We first determined whether any participant factors were associated with greater screening adherence at 6 months (Appendix Table 2 , available at www .annals.org). We then used multivariable logistic regression to evaluate the effect of study group on screening after adjusting for a priori-defined baseline participant characteristics. The adjusted OR was 0.88 (CI, 0.64 to 1.22) ( Among GERA recipients, average-risk participants had surprisingly higher screening rates than elevated-risk participants, although the OR of 0.60 (CI, 0.33 to 1.07) was not significant ( Table 4) . Of note, 85% (437 of 514) of GERA participants were considered in this analysis. The remaining 77 were considered to have unknown risk as described earlier (Figure) .
Because screening uptake did not differ between risk groups, we investigated whether any baseline factors may have confounded our results among participants randomly assigned to GERA ( Table 5) . Black participants were significantly more likely than white participants to be at elevated risk, presumably because of well-described differences in allele distribution frequency across race (OR, 5. To adjust for potential confounding, we fit a multivariable logistic model, including all covariates, to assess the effect of elevated-versus average-risk designation on CRC screening. The adjusted OR was 0.75 (CI, 0.39 to 1.42). The results of this analysis did not alter the conclusion that GERA risk classification did not significantly affect screening behavior (Appendix Table 3 , available at www.annals.org). † 6 participants (5 in the GERA group and 1 in the usual care group) had missing data in the chart review. We included these participants in the "no-screening" group in accordance with the intention-to-treat approach. CRC ϭ colorectal cancer; GERA ϭ genetic and environmental risk assessment; IQR ϭ interquartile range. * Data are numbers (percentages) unless otherwise indicated. None of the characteristics differed by study group (P Ͼ 0.05 for all [Pearson chi-square and Wilcoxon rank-sum tests used for categorical and continuous variables, respectively]). † Missing data excluded (n ϭ 1 for marital status; n ϭ 1 for education; n ϭ 2 for Impact of Event Scale score). ‡ Higher score indicates higher stress level. § Number of correct responses (10 items in each questionnaire). Higher score indicates greater knowledge level.
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We did additional analyses to control for potential confounders in the association between GERA risk group and CRC screening by using propensity score-based methods (Appendix). In a propensity score-matched analysis with 58 pairs, the adjusted OR was 0.71 (CI, 0.34 to 1.48) (Appendix Table 4 , available at www.annals.org).
Because we had excluded GERA participants with unknown risk (n ϭ 77) from the comparison of elevated-and average-risk participants, we did sensitivity analyses (Appendix Table 5 , available at www.annals.org). None of the analyses indicated that exclusion of unknown-risk participants affected the conclusion that screening rates in the elevated-risk group were not significantly higher.
Finally, because of the inverse relationship between higher baseline IES score and subsequent screening (Appendix Table 2 ), we examined the specific association between concern about genetic testing results (measured via the MICRA questionnaire) and screening uptake. Of the 283 GERA recipients who indicated receiving risk results, 264 completed the MICRA questionnaire. Those designated as having elevated versus average risk had significantly higher total MICRA and subscale scores (Appendix Table 6 , available at www.annals.org). However, MICRA scores were not significantly associated with screening uptake.
DISCUSSION
Our study examined the effect of combined genetic (MTHFR genotype) and environmental (serum folate levels) assessment on subsequent CRC screening in averagerisk persons not currently adherent to screening. We found no significant difference in screening uptake at 6 months between those randomly assigned to GERA or usual care or between GERA participants identified as having elevated versus average risk.
A predominant claim in the media is that enhanced knowledge of individual genetic makeup will promote a healthier lifestyle (27, 28) , and several companies market gene testing services directly to patients. Personalized, gene-based risk assessment could motivate persons to initiate an array of health behaviors, ranging from cancer screening to smoking cessation (29) . However, most relevant research about the effect of genetic testing on health behavior decision making has focused on persons with high-risk, single-gene mutations. If personalized genetic information proves to be an effective motivator, its greatest benefit will come when testing expands to populations at average risk for common diseases.
To our knowledge, previous studies in this general arena have not emphasized specific disease risk but instead tended to concentrate on broader "lifestyle" issues of diet, exercise, and smoking cessation (4) . Those studies evaluating genetic feedback on cancer screening have had small sample sizes and focused exclusively on populations at substantially elevated risk for diseases like hereditary breast and ovarian cancer (those with BRCA1 or BRCA2 mutations) (29) or CRC (those with specific mutations associated with familial adenomatous polyposis or hereditary nonpolyposis CRC) (12) .
Overall, limited evidence suggests that moderately predictive, personalized information effectively promotes positive behavior change in average-risk settings (4, 30) . Our findings that the GERA intervention did not increase CRC screening are consistent with the limited published literature. For example, Bloss and colleagues (31) reported that screening test utilization did not change in an uncontrolled, convenience sample of persons who purchased an online genomics test.
There is concern that moderately predictive genetic testing may have a negative psychological effect by increasing alarm about newly identified risk or fear resulting from misinterpretation of imprecise information (13) . Although † 4 missing values were excluded from analyses (n ϭ 1 for marital status; n ϭ 1 for education; n ϭ 2 for Impact of Event Scale score). Original Research Risk Assessment and Colorectal Cancer Screening we found some increase in distress related to receipt of GERA results, this effect did not seem related to screening rates (Appendix Table 6 ). In addition, a lack of familiarity with genomics on the part of patients (and providers) has been cited as a concern limiting the effect of genetic testing (28) .
We did see a consistent increase over time in knowledge about CRC screening and the role of genetic risk (data not shown), suggesting that the educational component of the intervention was successful. However, neither baseline nor increasing postintervention knowledge was associated with screening uptake.
In a recent report by the National Science Foundation (32), the most important issue identified for social science researchers was how to motivate persons to change their behavior. Our study addresses an important question: Does an intervention built on participant-specific GERA increase utilization of a clinically effective risk reduction strategy, CRC screening? As used in our study, personalized GERA is ineffective in this role. Potential explanations worthy of future study include the possibility that persons with more behavioral risk factors focus on genetic, not behavioral, explanations as causes of potential illness (33) . As a result, they may be unable or unwilling to alter behavior to reduce risk. Similarly, some have speculated that genetic risk is perceived as immutable-hence, persons who carry such a predisposition may believe that their fate is sealed (29) .
Provision of cards for fecal immunochemical testing was intended to minimize screening barriers for motivated persons. However, additional efforts to facilitate screening utilization may have produced different results. Alternatively, despite consistent reminders about the value of accepted screening methods, some participants may have believed that GERA testing itself was a form of screening or that folate supplementation alone was adequate protection against CRC. Finally, perhaps the most likely explanation is that the perceived risk associated with moderately pre- § Missing values excluded (n ϭ 1 for marital status; n ϭ 1 for Impact of Event Scale score).
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Risk Assessment and Colorectal Cancer Screening www.annals.orgdictive testing is simply not great enough to motivate behavior change, particularly in persons not oriented toward healthy behaviors, such as cancer screening (27) . Our study has limitations. At present, for common diseases with a polygenic basis, nearly any genetic or genetic plus environmental assessment can identify only modest predisposition. Such testing is not intended to be deterministic (28) . We studied only 1 combination of genetic and environmental interaction. Other combinations or forms of personalized information could be more effective motivational tools. We also studied only 1 risk reduction behavior, CRC screening. A wide range of behavioral interventions has been tried with uneven effect to increase such screening. Hence, generalizability to other behavioral targets remains an open question. Finally, a better understanding of the effect of the perceived risk associated with GERA results might explain why our intervention was ineffective.
In summary, this large, randomized trial found no effect on CRC screening rates in an average-risk population exposed to personalized genetic and environmental risk information. Further study is required to assess whether other such information and different means of presenting individualized results for common diseases like CRC will spur more healthy behaviors to reduce risk. The role of genetic and molecular testing to predict response to specific therapeutic options in health care delivery is increasing; however, the potential for similar testing to motivate behavioral change is less clear. 
